Parallel processing of T cells and natural killer cells to enhance in vivo CAR T cell activity against blood and solid cancers
Abstract Objectives Despite their anti‐cancer properties, natural killer (NK) cells are discarded during CAR T cell manufacturing. NK cells display promising responses as a cell therapy, exhibiting remarkable safety at high doses. Moreover, NK cells have complementary cytokine profiles and distinct antigen‐recognition...